Meclizine, Seasickness
Conditions
Keywords
Seasickness, Plasma Levels, Meclizine
Brief summary
Motion sickness is a debilitating condition that can effect many crew members. Meclizine has long been known as an effective anti motion sickness drug. The response to the drug is variable - some are responders, while others are resistant to the drug. The aim of the present study is to examine whether there is a correlation between meclizine plasma levels and clinical response.
Interventions
Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
Sponsors
Medical Corps, Israel Defense Force
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Seasickness questioner (WIKER) score of 7. * Subjective functioning at 1 meter sea voyage - 5/10 and lower. * Subjects who were prescribed 25mg of meclizine. * Subjects who did not take any other drugs 48 prior to their participation in the study.
Exclusion criteria
* Known hearing loss or any vestibular impairment * Vertigo complains * Any ear infection * Use of Scopolamine based anti-seasickness drugs. * Use of meclizine 50mg.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Meclizine plasma levels | 2 hours after meclizine administration | ng/dl |
Contacts
Primary ContactYoni Evgeni Gutkovich, M.D/Ph.D
Backup ContactDror Tal, Ph.D
Outcome results
None listed